146 related articles for article (PubMed ID: 1846181)
21. Transcriptional initiation and postinitiation effects of murine leukemia virus long terminal repeat R-region sequences.
Cupelli LA; Lenz J
J Virol; 1991 Dec; 65(12):6961-8. PubMed ID: 1658385
[TBL] [Abstract][Full Text] [Related]
22. Mutation of all Runx (AML1/core) sites in the enhancer of T-lymphomagenic SL3-3 murine leukemia virus unmasks a significant potential for myeloid leukemia induction and favors enhancer evolution toward induction of other disease patterns.
Sørensen KD; Quintanilla-Martinez L; Kunder S; Schmidt J; Pedersen FS
J Virol; 2004 Dec; 78(23):13216-31. PubMed ID: 15542674
[TBL] [Abstract][Full Text] [Related]
23. Regulatory elements within the murine leukemia virus enhancer regions mediate glucocorticoid responsiveness.
Celander D; Hsu BL; Haseltine WA
J Virol; 1988 Apr; 62(4):1314-22. PubMed ID: 2831392
[TBL] [Abstract][Full Text] [Related]
24. Murine leukemia virus long terminal repeat sequences can enhance gene activity in a cell-type-specific manner.
Yoshimura FK; Davison B; Chaffin K
Mol Cell Biol; 1985 Oct; 5(10):2832-5. PubMed ID: 3016518
[TBL] [Abstract][Full Text] [Related]
25. SL3-3 enhancer factor 1 transcriptional activators are required for tumor formation by SL3-3 murine leukemia virus.
Hallberg B; Schmidt J; Luz A; Pedersen FS; Grundström T
J Virol; 1991 Aug; 65(8):4177-81. PubMed ID: 1649324
[TBL] [Abstract][Full Text] [Related]
26. Evidence that a major class of mouse endogenous long terminal repeats (LTRs) resulted from recombination between exogenous retroviral LTRs and similar LTR-like elements (LTR-IS).
Schmidt M; Glöggler K; Wirth T; Horak I
Proc Natl Acad Sci U S A; 1984 Nov; 81(21):6696-700. PubMed ID: 6093113
[TBL] [Abstract][Full Text] [Related]
27. Binding of SL3-3 enhancer factor 1 transcriptional activators to viral and chromosomal enhancer sequences.
Thornell A; Hallberg B; Grundström T
J Virol; 1991 Jan; 65(1):42-50. PubMed ID: 1985206
[TBL] [Abstract][Full Text] [Related]
28. Increased lymphomagenicity and restored disease specificity of AML1 site (core) mutant SL3-3 murine leukemia virus by a second-site enhancer variant evolved in vivo.
Ethelberg S; Lovmand J; Schmidt J; Luz A; Pedersen FS
J Virol; 1997 Oct; 71(10):7273-80. PubMed ID: 9311802
[TBL] [Abstract][Full Text] [Related]
29. Retroviral vectors containing chimeric promoter/enhancer elements exhibit cell-type-specific gene expression.
Couture LA; Mullen CA; Morgan RA
Hum Gene Ther; 1994 Jun; 5(6):667-77. PubMed ID: 7948129
[TBL] [Abstract][Full Text] [Related]
30. The nucleotide sequence of the high-leukemogenic murine retrovirus SL3-3 reveals a patch of mink cell focus forming-like sequences upstream of the ecotropic envelope gene. Brief report.
Lund AH; Pedersen FS
Arch Virol; 1999; 144(11):2207-12. PubMed ID: 10603174
[TBL] [Abstract][Full Text] [Related]
31. Various modes of basic helix-loop-helix protein-mediated regulation of murine leukemia virus transcription in lymphoid cell lines.
Nielsen AL; Nørby PL; Pedersen FS; Jørgensen P
J Virol; 1996 Sep; 70(9):5893-901. PubMed ID: 8709209
[TBL] [Abstract][Full Text] [Related]
32. Extra mouse mammary tumor proviruses in DBA/2 mouse lymphomas acquire a selective advantage in lymphocytes by alteration in the U3 region of the long terminal repeat.
Yanagawa S; Murakami A; Tanaka H
J Virol; 1990 Jun; 64(6):2474-83. PubMed ID: 2159524
[TBL] [Abstract][Full Text] [Related]
33. The secondary structure of the R region of a murine leukemia virus is important for stimulation of long terminal repeat-driven gene expression.
Cupelli L; Okenquist SA; Trubetskoy A; Lenz J
J Virol; 1998 Oct; 72(10):7807-14. PubMed ID: 9733816
[TBL] [Abstract][Full Text] [Related]
34. An enhancer sequence instability that diversifies the cell repertoire for expression of a murine leukemia virus.
Spiro C; Li JP; Bestwick RK; Kabat D
Virology; 1988 Jun; 164(2):350-61. PubMed ID: 2835856
[TBL] [Abstract][Full Text] [Related]
35. CBF, Myb, and Ets binding sites are important for activity of the core I element of the murine retrovirus SL3-3 in T lymphocytes.
Zaiman AL; Nieves A; Lenz J
J Virol; 1998 Apr; 72(4):3129-37. PubMed ID: 9525638
[TBL] [Abstract][Full Text] [Related]
36. Increased induction of osteopetrosis, but unaltered lymphomagenicity, by murine leukemia virus SL3-3 after mutation of a nuclear factor 1 site in the enhancer.
Ethelberg S; Tzschaschel BD; Luz A; Diaz-Cano SJ; Pedersen FS; Schmidt J
J Virol; 1999 Dec; 73(12):10406-15. PubMed ID: 10559359
[TBL] [Abstract][Full Text] [Related]
37. A protein-binding site with dyad symmetry in the long terminal repeat of the MCF13 murine leukemia virus that contributes to transcriptional activity in T lymphocytes.
Yoshimura FK; Diem K; Chen H; Tupper J
J Virol; 1993 Apr; 67(4):2298-304. PubMed ID: 8383242
[TBL] [Abstract][Full Text] [Related]
38. Tumorigenic potential of a recombinant retrovirus containing sequences from Moloney murine leukemia virus and feline leukemia virus.
Starkey CR; Lobelle-Rich PA; Granger SW; Brightman BK; Fan H; Levy LS
J Virol; 1998 Feb; 72(2):1078-84. PubMed ID: 9445002
[TBL] [Abstract][Full Text] [Related]
39. Enhancer functions in U3 of Akv virus: a role for cooperativity of a tandem repeat unit and its flanking DNA sequences.
Lovmand S; Kjeldgaard NO; Jørgensen P; Pedersen FS
J Virol; 1990 Jul; 64(7):3185-91. PubMed ID: 2161937
[TBL] [Abstract][Full Text] [Related]
40. Addition of substitution of simian virus 40 enhancer sequences into the Moloney murine leukemia virus (M-MuLV) long terminal repeat yields infectious M-MuLV with altered biological properties.
Hanecak R; Pattengale PK; Fan H
J Virol; 1988 Jul; 62(7):2427-36. PubMed ID: 2836623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
